PVLA Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

11 Analyst Rating

Wall Street analysts forecast PVLA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PVLA is 132.55 USD with a low forecast of 70.00 USD and a high forecast of 200.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

11 Buy

0 Hold

0 Sell

Strong Buy

Current: 91.050

Low

70.00

Averages

132.55

High

200.00

Current: 91.050

Low

70.00

Averages

132.55

High

200.00

BTIG

Buy

initiated

$167

2025-12-05

Reason

BTIG

Price Target

$167

2025-12-05

initiated

Buy

Reason

BTIG initiated coverage of Palvella Therapeutics with a Buy rating and $167 price target. Palvella is a clinical stage biopharmaceutical company advancing its Qtorin topical delivery platform to address serious, rare skin diseases with no FDA-approved therapies, the analyst tells investors in a research note. The firm views the company as an "exceptionally clean biopharma story." Palvella's lead asset Qtorin rapamycin is nearing "value inflecting" Phase 2 and 3 readouts for cutaneous venous malformations and microcystic lymphatic malformations, notes BTIG. It sees blockbuster peak sales potential across "uncontested" indications.

Craig-Hallum

Albert Lowe

initiated

$175

2025-12-04

Reason

Craig-Hallum

Albert Lowe

Price Target

$175

2025-12-04

initiated

Reason

Craig-Hallum analyst Albert Lowe initiated coverage of Palvella Therapeutics with a Buy rating and $175 price target.

Craig-Hallum

Albert Lowe

initiated

$175

2025-12-04

Reason

Craig-Hallum

Albert Lowe

Price Target

$175

2025-12-04

initiated

Reason

As previously reported, Craig-Hallum analyst Albert Lowe initiated coverage of Palvella Therapeutics with a Buy rating and $175 price target. The firm sees upside as it expects upcoming catalysts to validate Qtorin rapamycin's potential as a novel topical therapy for serious, rare skin diseases, namely Phase II data in cutaneous venous malformations in mid-December and Phase III data in microcystic lymphatic malformations in Q1 2026. Craig-Hallum believes Qtorin rapamycin represents an over $2B peak sales opportunity across mLM and cVM as the uncontested standard of care in these rare disease settings. The firm's long-term outlook includes value-creating milestones as Qtorin rapamycin expands further to become a pipeline in a product and the newly announced asset Qtorin pitavastatin follows a similar roadmap to address untapped opportunities across rare skin diseases.

Clear Street

initiated

$200

2025-12-04

Reason

Clear Street

Price Target

$200

2025-12-04

initiated

Reason

Clear Street initiated coverage of Palvella Therapeutics with a Buy rating and $200 price target. The firm says the company is grouping its "highly differentiated" Qtorin rapamycin with a rare-disease strategy focused on orphan dermatologic indications that lack FDA-approved options but are "genetically" de-risked for rapamycin. The shares screen as "materially undervalued" ahead of Palvella's Phase 2 readout in cutaneous venous malformations expected by mid-December.

Stifel

Buy

maintain

$87 -> $145

2025-11-24

Reason

Stifel

Price Target

$87 -> $145

2025-11-24

maintain

Buy

Reason

Stifel raised the firm's price target on Palvella Therapeutics to $145 from $87 and keeps a Buy rating on the shares. Despite the "tremendous outperformance of shares," the firm still sees room for upside, not just from the Phase 2 TOIVA proof-of-concept trial data for QTORIN rapamycin 3.9% in cVMs due in mid-December but also the "numerous value-creating programs" it sees coming from the QTORIN platform, the analyst tells investors.

Raymond James

Outperform -> Strong Buy

upgrade

$92 -> $143

2025-11-19

Reason

Raymond James

Price Target

$92 -> $143

2025-11-19

upgrade

Outperform -> Strong Buy

Reason

Raymond James upgraded Palvella Therapeutics to Strong Buy from Outperform with a price target of $143, up from $92. After further review of precedent studies and the broader rationale for QTORIN rapamycin in cutaneous venous malformations ahead of the mid-December Phase 2 TOIVA readout, the case for efficacy appears strong based on oral rapamycin data, prior QTORIN success in microcystic lymphatic malformations, and its favorable safety and absorption profile, the analyst tells investors in a research note. Although buyside expectations sit somewhat above Palvella's internal 30% improvement threshold, the upcoming readout is more likely than not to meet both benchmarks and reinforce the program's broad potential, Raymond James argues.

Valuation Metrics

The current forward P/E ratio for Palvella Therapeutics Inc (PVLA.O) is -25.50, compared to its 5-year average forward P/E of -12.31. For a more detailed relative valuation and DCF analysis to assess Palvella Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-12.31

Current PE

-25.50

Overvalued PE

-5.91

Undervalued PE

-18.71

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-9.36

Current EV/EBITDA

-23.48

Overvalued EV/EBITDA

-2.62

Undervalued EV/EBITDA

-16.09

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

9405.03

Current PS

52560.41

Overvalued PS

26848.47

Undervalued PS

-8038.41

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

PVLA News & Events

Events Timeline

No data

News

9.0

09:00 AMNASDAQ.COM

PinnedPalvella Therapeutics Announces Encouraging Phase 2 Outcomes for QTORIN Rapamycin Gel

9.0

11:22 AMGlobenewswire

Palvella Reports 73% Improvement in Phase 2 QTORIN™ Trial for Cutaneous Venous Malformations

2.0

11:12 AMNewsfilter

Palvella Reports 73% Improvement in Phase 2 Trial of QTORIN™ for Cutaneous Venous Malformations

People Also Watch

Frequently Asked Questions

What is Palvella Therapeutics Inc (PVLA) stock price today?

The current price of PVLA is 91.05 USD — it has decreased -7.64 % in the last trading day.

What is Palvella Therapeutics Inc (PVLA)'s business?

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. The Company is developing a pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Its QTORIN product candidates are developed to accommodate the cargo at high concentrations in order to drive sufficient drug to its target deep in the epidermis and dermis. The Company's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is being evaluated in the Phase III SELVA clinical trial in microcystic lymphatic malformations and the Phase II TOIVA clinical trial in cutaneous venous malformations.

What is the price predicton of PVLA Stock?

What is Palvella Therapeutics Inc (PVLA)'s revenue for the last quarter?

Palvella Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is Palvella Therapeutics Inc (PVLA)'s earnings per share (EPS) for the last quarter?

Palvella Therapeutics Inc. EPS for the last quarter amounts to -1.03 USD, decreased -73.86 % YoY.

What changes have occurred in the market's expectations for Palvella Therapeutics Inc (PVLA)'s fundamentals?

The market is revising Downward the revenue expectations for Palvella Therapeutics, Inc. (PVLA) for FY2026, with the revenue forecasts being adjusted by -7.68% over the past three months. During the same period, the stock price has changed by 66.67%.

How many employees does Palvella Therapeutics Inc (PVLA). have?

Palvella Therapeutics Inc (PVLA) has 14 emplpoyees as of December 15 2025.

What is Palvella Therapeutics Inc (PVLA) market cap?

Today PVLA has the market capitalization of 1.17B USD.